These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9375024)

  • 21. The validity of the labelling index in tumour studies.
    Hamilton E; Dobbin J
    Br J Cancer; 1985 Jan; 51(1):15-21. PubMed ID: 3966970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cell kinetics in breast cancer.
    Becciolini A; Balzi M; Boanini P; Maugeri A; Pacini P; Bianchi S; Cardona G; Messeri G; Cataliotti L
    In Vivo; 1993; 7(6B):627-9. PubMed ID: 8193284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heterogeneity of intratumour proliferative activity in primary breast cancer: biological and clinical aspects.
    Paradiso A; Mangia A; Barletta A; Fusilli S; Marzullo F; Schittulli F; De Lena M
    Eur J Cancer; 1995 Jun; 31A(6):911-6. PubMed ID: 7646920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Growth kinetics of human colorectal carcinoma.
    Ota DM; Drewinko B
    Cancer Res; 1985 May; 45(5):2128-31. PubMed ID: 3986766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Distinct expression patterns of the transcription factor E2F-1 in relation to tumour growth parameters in common human carcinomas.
    Zacharatos P; Kotsinas A; Evangelou K; Karakaidos P; Vassiliou LV; Rezaei N; Kyroudi A; Kittas C; Patsouris E; Papavassiliou AG; Gorgoulis VG
    J Pathol; 2004 Jul; 203(3):744-53. PubMed ID: 15221933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer biology for individualized therapy: correlation of growth fraction index in native-state histoculture with tumor grade and stage.
    Vescio RA; Connors KM; Youngkin T; Bordin GM; Robb JA; Umbreit JN; Hoffman RM
    Proc Natl Acad Sci U S A; 1990 Jan; 87(2):691-5. PubMed ID: 2153963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of survival by thymidine labelling index in patients with resistant ovarian carcinoma.
    Alama A; Merlo F; Chiara S; Muttini MP; Guido T; Nicolò G; Conte PF; Ragni N
    Eur J Cancer; 1992; 28A(6-7):1079-80. PubMed ID: 1627379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ki-67 labeling index is a more reliable measure of solid tumor proliferative activity than tritiated thymidine labeling.
    Deshmukh P; Ramsey L; Garewal HS
    Am J Clin Pathol; 1990 Aug; 94(2):192-5. PubMed ID: 2371973
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cell proliferation and outcome following doxorubicin plus CMF regimens in node-positive breast cancer.
    Silvestrini R; Luisi A; Zambetti M; Cipriani S; Valagussa P; Bonadonna G; Daidone MG
    Int J Cancer; 2000 Aug; 87(3):405-11. PubMed ID: 10897047
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Significance of the Tritiated Thymidine Labeling Index in breast cancers.
    Araki K; Kimura M; Sakamoto K; Nishimura R; Akagi M
    Jpn J Surg; 1985 Mar; 15(2):144-9. PubMed ID: 4010096
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The errors of thymidine labelling in breast cancer.
    Smallwood JA; Cooper A; Taylor I
    Clin Oncol; 1983 Dec; 9(4):331-5. PubMed ID: 6661855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PCNA immunostaining as a valid alternative to tritiated thymidine-autoradiography to detect proliferative cell fraction in transitional cell bladder carcinomas.
    Lavezzi AM; Terni L; Matturri L
    In Vivo; 2000; 14(3):447-51. PubMed ID: 10904880
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinoma in situ.
    Barnes DM; Meyer JS; Gonzalez JG; Gullick WJ; Millis RR
    Breast Cancer Res Treat; 1991 Mar; 18(1):11-7. PubMed ID: 1677296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heterogeneity of mitotic activity in breast cancer.
    Jannink I; Risberg B; Van Diest PJ; Baak JP
    Histopathology; 1996 Nov; 29(5):421-8. PubMed ID: 8951486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Cell kinetic investigations in fibrocystic mastopathies and invasive breast carcinomas].
    Kunz J
    Acta Histochem Suppl; 1990; 39():175-9. PubMed ID: 2080259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between the thymidine labeling and Ki-67 proliferative indices in 126 breast cancer patients.
    Molino A; Pedersini R; Micciolo R; Frisinghelli M; Giovannini M; Pavarana M; Nortilli R; Santo A; Manno P; Padovani M; Piubello Q; Cetto GL
    Appl Immunohistochem Mol Morphol; 2002 Dec; 10(4):304-9. PubMed ID: 12607597
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reliability and stability of the thymidine labeling index of breast carcinoma.
    Meyer JS; McDivitt RW
    Lab Invest; 1986 Feb; 54(2):160-4. PubMed ID: 3945050
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proliferative index of breast carcinoma by thymidine labeling: prognostic power independent of stage, estrogen and progesterone receptors.
    Meyer JS; Province M
    Breast Cancer Res Treat; 1988 Oct; 12(2):191-204. PubMed ID: 3242648
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of dietary wheat bran fiber on rectal epithelial cell proliferation in patients with resection for colorectal cancers.
    Alberts DS; Einspahr J; Rees-McGee S; Ramanujam P; Buller MK; Clark L; Ritenbaugh C; Atwood J; Pethigal P; Earnest D
    J Natl Cancer Inst; 1990 Aug; 82(15):1280-5. PubMed ID: 2165179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tritiated thymidine labelling in vitro of human cancer of the breast: counting error and sampling error.
    Lambert M
    Eur J Cancer Clin Oncol; 1986 Jul; 22(7):781-5. PubMed ID: 3770036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.